Citi initiated coverage of Celldex with a Buy rating and $70 price target Celldex is evaluating barzolvolimab, a KIT inhibitor, across a range of mast cell-mediated diseases, the analyst tells investors in a research note. The firm says barzolvolimab’s lead program in chronic spontaneous urticaria has been “meaningfully de-risked” given promising Phase 2 data, “which highlighted compelling efficacy that compares favorably to the only approved therapy for the disease, Xolair.” It also believes barzolvolimab is well positioned to be the first therapy approved to treat chronic inducible urticaria, with additional upside from future expansion opportunities.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDX:
- Disney upgraded, JPMorgan downgraded: Wall Street’s top analyst calls
- Celldex initiated with a Neutral at Goldman Sachs
- Wolfe Research cuts Celldex to Peer Perform, sees negative risk-reward skew
- Celldex downgraded to Peer Perform from Outperform at Wolfe Research
- Jasper concerns driven by Celldex data ‘overdone,’ says Stifel